2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1319

Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
Abstract Number: 1509

Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Abstract Number: 1476

Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Abstract Number: 1489

Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Abstract Number: 1513

Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
Abstract Number: 516

Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Abstract Number: 284

Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis : Multicenter and Cross-sectional Study
Abstract Number: 1523

Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Abstract Number: 2119

Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis
Abstract Number: 1581

Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Abstract Number: 2079

Impact of Eliminating the Bouted Minutes Requirement in the New 2018 Physical Activity Guidelines for Americans on Gender Disparity in Guideline Attainment for Persons with or at High Risk of Knee Osteoarthritis
Abstract Number: 2455

Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Abstract Number: 533

Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients
Abstract Number: 844

Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial
Abstract Number: 359

Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].